Mochida Pharmaceutical Co (FRA:MFY) EPS without NRI: €1.27 (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:MFY Mochida Pharmaceutical Co Ltd FRA:MFY
63 GF Score
Price €16.40
GF Value €19.38
! 4 Warning Signs
View Full Analysis

What is Mochida Pharmaceutical Co EPS without NRI?

Mochida Pharmaceutical Co FRA:MFY -0.61% 63 EPS without NRI is €1.27 as of Mar. 2026. GuruFocus rates FRA:MFY with a GF Score™ of 63/100 and a GF Value™ of €19.38. The stock has 4 warning signs investors should review. Among 790 Drug Manufacturers companies, Mochida Pharmaceutical Co ranks worse than 53.67% on this metric.

Mochida Pharmaceutical Co's earnings per share without non-recurring items for the three months ended in Mar. 2026 was €0.24. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €1.27.

During the past 12 months, Mochida Pharmaceutical Co's average earnings per share (NRI) Growth Rate was 39.10% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 7.50% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -6.00% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was -2.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Mochida Pharmaceutical Co's EPS without NRI or its related term are showing as below:

FRA:MFY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -18.4   Med: 2.8   Max: 38.9
Current: 7.5

During the past 13 years, Mochida Pharmaceutical Co's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 38.90% per year. The lowest was -18.40% per year. And the median was 2.80% per year.

FRA:MFY's 3-Year EPS without NRI Growth Rate is ranked worse than
53.67% of 790 companies
in the Drug Manufacturers industry
Industry Median: 9.6 vs FRA:MFY: 7.50

Mochida Pharmaceutical Co's EPS (Diluted) for the three months ended in Mar. 2026 was €0.24. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €1.26.

Mochida Pharmaceutical Co's EPS (Basic) for the three months ended in Mar. 2026 was €0.24. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €1.26.


Mochida Pharmaceutical Co  (FRA:MFY) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Mochida Pharmaceutical Co EPS without NRI Related Terms


Mochida Pharmaceutical Co EPS without NRI Historical Data

* Premium members only.

The historical data trend for Mochida Pharmaceutical Co's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mochida Pharmaceutical Co EPS without NRI Chart

Mochida Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.15 1.26 0.76 1.00 1.22

Mochida Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.32 0.32 0.38 0.24

FRA:MFY vs ZTS, UTHR: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Mochida Pharmaceutical Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mochida Pharmaceutical Co PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mochida Pharmaceutical Co's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Mochida Pharmaceutical Co's PE Ratio without NRI falls into.


FRA:MFY
63GF Score
Mochida Pharmaceutical Co Ltd FRA:MFY
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mochida Pharmaceutical Co EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of €1.27 mean?
Mochida Pharmaceutical Co (FRA:MFY) has a EPS without NRI of €1.27 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Mochida Pharmaceutical Co and its competitors. According to the industry distribution chart, Mochida Pharmaceutical Co ranks #424 out of 790 companies in the Drug Manufacturers industry, placing it in the top 53.7%.
Is Mochida Pharmaceutical Co's EPS without NRI too high?
Mochida Pharmaceutical Co's current EPS without NRI is €1.27. Based on the distribution chart, Mochida Pharmaceutical Co ranks #424 out of 790 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Mochida Pharmaceutical Co has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Mochida Pharmaceutical Co's EPS without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Mochida Pharmaceutical Co ranks #424 out of 790 companies for EPS without NRI. This places Mochida Pharmaceutical Co in the lower half of its industry. The industry median EPS without NRI is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.60, based on 790 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Mochida Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mochida Pharmaceutical Co's current EPS without NRI is €1.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mochida Pharmaceutical Co stock overvalued right now?
Mochida Pharmaceutical Co (FRA:MFY) has a current EPS without NRI of €1.27. The stock's GF Value™ is €19.38, compared to a current price of €16.40 — trading 15.4% below its estimated fair value. The current EPS without NRI is €1.27. Mochida Pharmaceutical Co's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Mochida Pharmaceutical Co (FRA:MFY), the current EPS without NRI is €1.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mochida Pharmaceutical Co (FRA:MFY) Overvalued in 2026?

Based on GuruFocus' analysis, Mochida Pharmaceutical Co stock appears to be undervalued. The current stock price of €16.40 is trading 15.4% below its estimated GF Value™ of €19.38.

Key valuation signals for FRA:MFY:

  • EPS without NRI: €1.27
  • GF Value™: €19.38 vs. price of €16.40 (15.4% below fair value)
  • GF Score™: 63/100 with 4 warning signs

No single metric tells the full story. See the FRA:MFY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mochida Pharmaceutical Co Business Description

Other Exchanges 4534:Japan
Address 1-1 Ichigayahonmuracho, Shinjuku-ku, Tokyo, JPN, 162-0845
Mochida Pharmaceutical Co Ltd is a major drug manufacturing company that operates in the field of medical care through its pharmaceuticals, healthcare products, and medical equipment businesses. The company's pharmaceuticals business aims to develop and market a broad spectrum of innovative new drugs. One of Mochida's main objectives is to maximize the business performance of its drugs after they are developed and released. The company also creates skin care products for the general public, and these are supplied through pharmacies, drugstores, and mail-order sales.
63GF Score

Get the complete analysis for FRA:MFY

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.40
Price
€19.38
GF Value